Eastern Bank Has $36.92 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Eastern Bank more than doubled its Johnson & Johnson position in the second quarter, increasing holdings by 125.2% to 145,368 shares valued at approximately $36.92 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly EPS of $2.90, beating estimates by $0.06, while revenue rose 6.6% year over year to $25.31 billion. The company also declared a quarterly dividend of $1.34 per share, equivalent to a 2.1% annual yield.
• Analysts remain broadly positive, with JNJ carrying a “Moderate Buy” consensus rating and an average price target of $267.48. Recent growth catalysts include FDA authorization for its OTTAVA robotic-surgery system and strong oncology performance, although competition and the stock’s elevated valuation remain risks.

Eastern Bank increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 125.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,368 shares of the company's stock after acquiring an additional 80,814 shares during the period. Eastern Bank's holdings in Johnson & Johnson were worth $36,919,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Brighton Jones LLC raised its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares in the last quarter. United Bank increased its holdings in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company's stock worth $1,539,000 after purchasing an additional 4,876 shares during the period. Sivia Capital Partners LLC increased its stake in Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after acquiring an additional 692 shares during the period. Wealth Group Ltd. raised its stake in shares of Johnson & Johnson by 12.8% in the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock valued at $226,000 after purchasing an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. lifted its holdings in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after acquiring an additional 6,584 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.7%

JNJ stock opened at $254.54 on Tuesday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $246.25 and a two-hundred day moving average price of $238.80. Johnson & Johnson has a twelve month low of $166.64 and a twelve month high of $274.90. The company has a market cap of $613.41 billion, a price-to-earnings ratio of 29.49, a P/E/G ratio of 2.43 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. During the same quarter last year, the company posted $2.77 earnings per share. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts anticipate that Johnson & Johnson will post 11.69 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's payout ratio is 62.11%.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. Wells Fargo & Company boosted their price target on Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research note on Monday. TD Cowen boosted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. Leerink Partners raised shares of Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 target price on the stock in a research note on Wednesday, May 13th. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Finally, Citigroup upped their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $267.48.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received FDA authorization for OTTAVA, its robotic-assisted surgical system, and is preparing for market introduction. Management discussed the system’s design, potential operating-room benefits and commercialization plans, creating a potential new growth platform beyond JNJ’s established pharmaceutical and medical-device businesses. Johnson & Johnson Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System
• Positive Sentiment: Commentary from Jim Cramer characterized OTTAVA’s FDA milestone as a catalyst that improved sentiment toward JNJ after investors initially underappreciated the company’s strong earnings report. The assessment is opinion-based, but it reflects increased visibility for the robotics opportunity. Jim Cramer Analyzes Johnson & Johnson After Surgical Robotics Milestone
• Positive Sentiment: Johnson & Johnson’s oncology business delivered strong second-quarter growth, supported by Darzalex, Erleada and newer cancer treatments. Continued oncology momentum could help offset mature-product pressure and support long-term earnings growth. J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes
• Positive Sentiment: Wells Fargo raised its JNJ price target from $272 to $282 and maintained an “overweight” rating, signaling confidence in the company’s earnings outlook and growth initiatives. Wells Fargo Price Target Update
• Positive Sentiment: Reports also highlighted a roughly $3.5 billion biotech transaction or strategic move that expands JNJ’s oncology pipeline, potentially strengthening its future pharmaceutical portfolio. Johnson & Johnson Oncology Pipeline Expansion
• Neutral Sentiment: Market coverage continues to present JNJ as a defensive, dividend-oriented value stock, particularly as technology shares weaken and healthcare attracts broader value-ETF inflows. This may support demand but is not a company-specific catalyst. The S&P 493 Are Staging a Comeback
• Negative Sentiment: OTTAVA must compete with robotic-surgery systems that entered the market earlier, so FDA authorization does not guarantee rapid adoption or meaningful near-term revenue. Investors may also view JNJ’s valuation as demanding after its strong run.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source